Skip to content
TubeRank.
Get app
HIMS

The call, on record

HIMS bullish call

Recorded from Asymmetric Investing by Travis Hoium’s public commentary. Review the evidence behind the call and its outcome.
HIMSBullNot scored
Asymmetric Investing by Travis HoiumAsymmetric Investing by Travis Hoium
Imported analysis · scheduled AI source · awaiting moderator review. The quote is source evidence; the structured call and thesis are TubeRank’s interpretation.
Quoted text as recorded“So I think this is the kind of company that could compound revenue 30 plus% over the course of 10 maybe even 20 years”@ 13:12 · open at this moment on YouTube ↗

Our interpretation

Source published
Oct 9, 2026
Timeframe
over the course of 10 maybe even 20 years
Interpreted confidence
low
Specificity
specific

Why this call is unscored

Status
Not scored
Notes
There is no numerical target that can be objectively scored.

How outcomes are decided · Report an error

Email me when HIMS calls resolve

When a tracked HIMS call is scored — hit, miss or partial — we’ll email you the result. No account needed.

Used only for these updates. Privacy

Follow Asymmetric Investing by Travis Hoium in the iPhone appEvery HIMS call on file

Evidence and source

Why I'm Betting Big on These 5 Growth Stocks
Published on Oct 9, 2026@ 13:12Open on YouTube

Our summary of the thesis

Strongly Bullish

Structured interpretation of the video, not a verbatim quotation. Check the source for conditions, emphasis and context.

The host believes Hims & Hers can sustain long-term revenue compounding through product expansion, international acquisitions, and a large healthcare opportunity. He expects growth to recover after disruption to compounded GLP-1 offerings.

Key arguments

  • The host reports a three-year revenue compound growth rate around 54%.
  • The product portfolio now includes Novo Nordisk and Eli Lilly products.
  • Labs, AI tools, and potential peptides broaden the offering.
  • International expansion increases the addressable market.
  • Enterprise value to sales around 2.8 appears inexpensive to the host.
  • Management's second-half growth guidance supports the recovery narrative.

Counter-arguments acknowledged

  • Restrictions on compounded GLP-1 products disrupted growth.
  • Novo Nordisk sued the company before a settlement.
  • First-quarter revenue growth slowed to approximately 3.8%.
  • The forward earnings multiple is approximately 81 and profitability is not the host's current focus.

Hedges and caveats (from the video)

  • Several holdings have struggled in 2026 despite revenue growth.
  • SoFi's technology platform has disappointed and lost Chime as a major customer.
  • Robinhood remains relatively expensive; the host trimmed his holding when its valuation became stretched.
  • Duolingo's growth has decelerated and its turnaround depends on engagement translating into paid subscriptions.
  • Hims & Hers has faced regulatory and legal challenges around compounded GLP-1 products.
  • Long-term revenue growth projections depend on successful execution.

About this record

Not yet reviewed by a moderator

Imported analysis · scheduled AI source. A quote, summary and outcome each need their own context. Moderator review does not certify investment performance.

Source published
Oct 9, 2026, 3:53 PM UTC
First recorded by TubeRank
Oct 9, 2026, 5:04 PM UTC
Record last updated
Oct 14, 2026, 11:40 AM UTC
Moderator review recorded
Not recorded
Transcript provenance
YouTube captions (manual or automatic)
Recorded analysis processor/source label
codex-cli-scheduled
This can identify a workflow rather than an exact AI model version.
Submission path version
manual_v1
Identifies the precomputed submission path. It does not identify an AI model version or imply human authorship.
Outcome methodology version
2026-10-06.5
Outcome reason code
missing_target
Publication is when the video was released; recording is when TubeRank added this call. They are not interchangeable. Legacy records can lack version and observation metadata. Dates are shown in UTC.
Recent record changes 2 shown

  1. Oct 14, 2026, 11:40 AM UTC

    missing target

    Outcome methodology version

    BeforeNot recorded

    After2026-10-06.5

    Recorded outcome date

    BeforeNot recorded

    After2026-10-14

    Outcome explanation

    BeforeNot recorded

    AfterThere is no numerical target that can be objectively scored.

    Outcome reason

    BeforeNot recorded

    AfterMissing target

  2. Oct 9, 2026, 5:04 PM UTC

    source updated

    Recorded analysis processor/source label

    BeforeNot recorded

    Aftercodex-cli-scheduled

    Extraction or submission version

    BeforeNot recorded

    Aftermanual_v1

Showing up to 20 recent changes. The complete feed has 3 recorded events for this call, including its initial entry. Read the full paginated history (JSON); follow nextCursor while hasMore is true.

Methodology and limitationsReport a correction
Stored outcome evidence
Stored reference price
Not recorded
Not recorded · provider not recorded
Target as extracted
Not recorded
Stated deadline as extracted
None recorded
Recorded outcome date
Oct 14, 2026
Outcome price observation
Not recorded
Not recorded · provider not recorded

Stored explanation

There is no numerical target that can be objectively scored.

Missing timestamps, providers and versions are historical gaps. Stored observations can include daily closes; they do not show every intraday touch or prove an executable trade. Read the methodology.

Why we interpreted the confidence this way

Base 5 minus 2 for 'could' gives 3; the longer horizon is additionally qualified by 'maybe'.

View full video analysisView YouTuber profile